Mustang Bio

Mustang Bio is a clinical-stage biopharma accelerating CAR‑T and oncolytic virus therapies for high‑impact cancers and immune disorders, including CD20‑CAR T for lymphoma/CLL, IL13Ra2‑CAR T for glioblastoma, and HSV‑1 oncolytic C134.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 6
HQ: Waltham

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
MBIO	Mustang Bio Cap: 0.0B	EQUITY	NMS	USD	US62818Q1040	Active	📈